Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1963 1
1968 1
1970 1
1971 1
1972 1
1973 1
1974 1
1975 1
1976 2
1977 3
1978 4
1979 3
1980 12
1981 8
1982 6
1983 4
1984 3
1985 11
1986 10
1987 12
1988 3
1989 10
1990 12
1991 8
1992 10
1993 8
1994 6
1995 10
1996 8
1997 10
1998 17
1999 8
2000 8
2001 10
2002 15
2003 16
2004 22
2005 18
2006 25
2007 24
2008 31
2009 29
2010 35
2011 30
2012 38
2013 43
2014 37
2015 41
2016 53
2017 33
2018 27
2019 31
2020 47
2021 55
2022 45
2023 33
2024 45
2025 41
2026 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

921 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.
Sternschuss M, White C, Quinlan C, Regazzi A, Jihad M, Chen J, McCoy A, Rafelson W, Laccetti A, Makris M, Al-Ahmadie H, Teo MY, Xiao H, Iyer G, Bajorin DF, Chaim JL, Ostrovnaya I, Rosenberg JE, O'Donnell PH, Mortazavi A, Funt SA. Sternschuss M, et al. Among authors: o donnell ph. Clin Genitourin Cancer. 2026 May 6;24(5):102577. doi: 10.1016/j.clgc.2026.102577. Online ahead of print. Clin Genitourin Cancer. 2026. PMID: 42217273
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.
Rosenberg JE, O'Donnell PH, Petrylak DP, Flaig TW, Hoimes CJ, Gupta S, Mar N, Friedlander TW, Tagawa ST, Bilen MA, Brown JR, McKay RR, Merchan JR, Srinivas S, Gorla S, Moreno BH, Davis G, Wirtz HS, Zhu Y, Milowsky MI. Rosenberg JE, et al. Among authors: o donnell ph. ESMO Open. 2026 May 19;11(6):107700. doi: 10.1016/j.esmoop.2026.107700. Online ahead of print. ESMO Open. 2026. PMID: 42155320 Free PMC article.
Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers: A Disordinal Effect.
Cecchi M, Johannesen J, Farley BJ, Quirk MC, Mahmoud-Zadeh M, Uslaner JM, Terry-Lorenzo R, Smith DG, Ruhl DA, Rotte M, Reese AL, O'Donnell P, Mollon JE, Missling C, Matsuoka Y, Marino MJ, Lee S, Korolev IO, Klamer D, Jeong A, Honda S, Fadem KC, Doherty J, Cohen EA, Christensen S, Chadchankar H, Buhl DL, Adachi M, D'Souza DC, Hamilton HK, Ranganathan M, Roach BJ, Ereshefsky L, Walling DP, Potter WZ, Javitt DC, Mathalon DH. Cecchi M, et al. Among authors: o donnell p. Biol Psychiatry. 2026 Apr 15:S0006-3223(26)01187-X. doi: 10.1016/j.biopsych.2026.03.1008. Online ahead of print. Biol Psychiatry. 2026. PMID: 41997476
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.
Economides MP, O'Donnell PH, Alva AS, Milowsky MI, Kollmeier M, Niglio S, Persily J, Sweis RF, Rose T, Iyer G, Spratt D, Palmbos P, Hochman T, Goldberg JD, Francese K, Griglun S, Leis D, Steinberg GD, Wysock J, Schiff PB, Sanfilippo NJ, Taneja SS, Wise DR, Huang WC, Balar AV. Economides MP, et al. Among authors: o donnell ph. Eur Urol. 2026 Apr 6:S0302-2838(26)02034-8. doi: 10.1016/j.eururo.2026.02.016. Online ahead of print. Eur Urol. 2026. PMID: 41945031
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Göger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullén A; KEYNOTE-905/EV-303 Investigators. Vulsteke C, et al. Among authors: o donnell ph. N Engl J Med. 2026 Apr 2;394(13):1257-1269. doi: 10.1056/NEJMoa2511674. Epub 2026 Feb 18. N Engl J Med. 2026. PMID: 41707170 Clinical Trial.
Incidence of and Risk Factors for Delayed Engraftment after Post-Transplant Cyclophosphamide.
Scarpetti L, Schwartz DE, Huang W, Ikeda D, Collier K, Chung J, DeFilipp Z, El-Jawahri A, Frigault MJ, McAfee S, Newcomb R, Spitzer TR, O'Donnell P, Chen YB. Scarpetti L, et al. Among authors: o donnell p. Transplant Cell Ther. 2026 Feb 13:S2666-6367(26)00143-0. doi: 10.1016/j.jtct.2026.02.040. Online ahead of print. Transplant Cell Ther. 2026. PMID: 41692395 No abstract available.
921 results